|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Kim, Y, Hammerman, PS, Kim, J, Yoon, JA, Lee, Y, Sun, JM, Wilkerson, MD, Pedamallu, CS, Cibulskis, K, Yoo, YK, Lawrence, MS, Stojanov, P, Carter, SL, McKenna, A, Stewart, C, Sivachenko, AY, Oh, IJ, Kim, HK, Choi, YS, Kim, K, Shim, YM, Kim, KS, Song, SY, Na, KJ, Choi, YL, Hayes, DN, Kim, J, Cho, S, Kim, YC, Ahn, JS, Ahn, MJ, Getz, G, Meyerson, M, Park, K|
|Journal||Journal of clinical oncology : official journal of the American Society of Clinical Oncology|
Lung squamous cell carcinoma (SCC) is the second most prevalent type of lung cancer. Currently, no targeted therapeutics are approved for treatment of this cancer, largely because of a lack of systematic understanding of the molecular pathogenesis of the disease. To identify therapeutic targets and perform comparative analyses of lung SCC, we probed somatic genome alterations of lung SCC by using samples from Korean patients.